{"id":50191,"date":"2025-12-08T22:00:15","date_gmt":"2025-12-08T14:00:15","guid":{"rendered":"https:\/\/flcube.com\/?p=50191"},"modified":"2025-12-08T22:00:16","modified_gmt":"2025-12-08T14:00:16","slug":"cspc-syh2069-glp-1-gip-dual-agonist-wins-fda-nod-for-obesity","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50191","title":{"rendered":"CSPC SYH2069 GLP-1\/GIP Dual Agonist Wins FDA Nod for Obesity"},"content":{"rendered":"\n<p><strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that <strong>SYH2069 Injection<\/strong>, its <strong>GLP-1\/GIP receptor dual-biased agonist polypeptide<\/strong>, has obtained <strong>FDA approval<\/strong> to conduct clinical trials in the US for <strong>weight management<\/strong> in individuals with obesity or overweight and at least one weight-related comorbidity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>CSPC Pharmaceutical Group Limited (1093.HK)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SYH2069 Injection<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>FDA clinical trial approval (US)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Weight management for obesity\/overweight with \u22651 comorbidity<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>GLP-1\/GIP receptor dual-biased agonist<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Long half-life modification platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-differentiation\">Mechanism of Action &amp; Differentiation<\/h2>\n\n\n\n<p><strong>Dual-Biased Agonist Design:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Selective cAMP activation<\/strong>: Preferentially activates cAMP pathway while markedly reducing \u03b2-arrestin recruitment<\/li>\n\n\n\n<li><strong>Reduced receptor internalization<\/strong>: Decreases desensitization, enhancing drug efficacy<\/li>\n\n\n\n<li><strong>Extended durability<\/strong>: Prolonged pharmacodynamic effect supports less frequent dosing<\/li>\n\n\n\n<li><strong>Long half-life platform<\/strong>: Integration of modification technology enables sustained weight loss<\/li>\n<\/ul>\n\n\n\n<p><strong>Preclinical Advantages:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Superior efficacy<\/strong>: Demonstrated significantly better weight loss and metabolic improvement vs. similar marketed products in diet-induced obesity (DIO) mice and non-human primates<\/li>\n\n\n\n<li><strong>Safety profile<\/strong>: Well-tolerated in repeat-dose toxicology studies; <strong>no vomiting or GI adverse reactions<\/strong> observed in NHPs<\/li>\n\n\n\n<li><strong>Next-generation potential<\/strong>: Positioned as potential new therapeutic agent for metabolic diseases beyond obesity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-outlook\">Market Context &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity Market<\/strong>: Global market projected <strong>$50 billion<\/strong> by 2030; US obesity population exceeds 100 million<\/li>\n\n\n\n<li><strong>GLP-1\/GIP Competition<\/strong>: Dominated by Eli Lilly\u2019s tirzepatide; CSPC\u2019s biased agonist offers differentiated mechanism<\/li>\n\n\n\n<li><strong>Clinical Advantage<\/strong>: Improved tolerability (no vomiting) addresses key barrier to GLP-1 therapy adherence<\/li>\n\n\n\n<li><strong>Development Timeline<\/strong>: Phase 1 initiation expected Q1\u202f2026; Phase 2 data anticipated H2\u202f2027<\/li>\n\n\n\n<li><strong>Commercial Path<\/strong>: US trial positions CSPC for global market entry; China filing may follow based on US data<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding SYH2069 development timelines, clinical outcomes, and market potential. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120501162_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025120501162_c.\"><\/object><a id=\"wp-block-file--media-4a6faf3e-c1f1-46e9-9264-6ea451da5325\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120501162_c.pdf\">2025120501162_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120501162_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4a6faf3e-c1f1-46e9-9264-6ea451da5325\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1\/GIP receptor dual-biased agonist&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50194,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,171,855,4361,86],"class_list":["post-50191","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093","tag-hot-targets","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC SYH2069 GLP-1\/GIP Dual Agonist Wins FDA Nod for Obesity - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1\/GIP receptor dual-biased agonist polypeptide, has obtained FDA approval to conduct clinical trials in the US for weight management in individuals with obesity or overweight and at least one weight-related comorbidity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50191\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC SYH2069 GLP-1\/GIP Dual Agonist Wins FDA Nod for Obesity\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1\/GIP receptor dual-biased agonist polypeptide, has obtained FDA approval to conduct clinical trials in the US for weight management in individuals with obesity or overweight and at least one weight-related comorbidity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50191\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T14:00:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-08T14:00:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0810.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50191#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50191\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC SYH2069 GLP-1\\\/GIP Dual Agonist Wins FDA Nod for Obesity\",\"datePublished\":\"2025-12-08T14:00:15+00:00\",\"dateModified\":\"2025-12-08T14:00:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50191\"},\"wordCount\":305,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50191#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0810.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"Hot targets\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50191#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50191\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50191\",\"name\":\"CSPC SYH2069 GLP-1\\\/GIP Dual Agonist Wins FDA Nod for Obesity - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50191#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50191#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0810.webp\",\"datePublished\":\"2025-12-08T14:00:15+00:00\",\"dateModified\":\"2025-12-08T14:00:16+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1\\\/GIP receptor dual-biased agonist polypeptide, has obtained FDA approval to conduct clinical trials in the US for weight management in individuals with obesity or overweight and at least one weight-related comorbidity.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50191#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50191\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50191#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0810.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0810.webp\",\"width\":1080,\"height\":608,\"caption\":\"CSPC SYH2069 GLP-1\\\/GIP Dual Agonist Wins FDA Nod for Obesity\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50191#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC SYH2069 GLP-1\\\/GIP Dual Agonist Wins FDA Nod for Obesity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC SYH2069 GLP-1\/GIP Dual Agonist Wins FDA Nod for Obesity - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1\/GIP receptor dual-biased agonist polypeptide, has obtained FDA approval to conduct clinical trials in the US for weight management in individuals with obesity or overweight and at least one weight-related comorbidity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50191","og_locale":"en_US","og_type":"article","og_title":"CSPC SYH2069 GLP-1\/GIP Dual Agonist Wins FDA Nod for Obesity","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1\/GIP receptor dual-biased agonist polypeptide, has obtained FDA approval to conduct clinical trials in the US for weight management in individuals with obesity or overweight and at least one weight-related comorbidity.","og_url":"https:\/\/flcube.com\/?p=50191","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-08T14:00:15+00:00","article_modified_time":"2025-12-08T14:00:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0810.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50191#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50191"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC SYH2069 GLP-1\/GIP Dual Agonist Wins FDA Nod for Obesity","datePublished":"2025-12-08T14:00:15+00:00","dateModified":"2025-12-08T14:00:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50191"},"wordCount":305,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50191#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0810.webp","keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093","Hot targets","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50191#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50191","url":"https:\/\/flcube.com\/?p=50191","name":"CSPC SYH2069 GLP-1\/GIP Dual Agonist Wins FDA Nod for Obesity - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50191#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50191#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0810.webp","datePublished":"2025-12-08T14:00:15+00:00","dateModified":"2025-12-08T14:00:16+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1\/GIP receptor dual-biased agonist polypeptide, has obtained FDA approval to conduct clinical trials in the US for weight management in individuals with obesity or overweight and at least one weight-related comorbidity.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50191#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50191"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50191#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0810.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0810.webp","width":1080,"height":608,"caption":"CSPC SYH2069 GLP-1\/GIP Dual Agonist Wins FDA Nod for Obesity"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50191#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC SYH2069 GLP-1\/GIP Dual Agonist Wins FDA Nod for Obesity"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0810.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50191"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50191\/revisions"}],"predecessor-version":[{"id":50195,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50191\/revisions\/50195"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50194"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}